DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for anogenital venereal wart — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAnogenital venereal wart maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for anogenital venereal wart is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interferon alpha and beta receptor subunit 1 (IFNAR1) — IFNAR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3SE4 · 3.5001 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No single preferable therapy exists for anogenital warts, and an established effective treatment is lacking. A 2004 literature review notes that available treatments include physical and chemical destruction, surgical removal, and biological response modifiers, but therapy can be painful and expensive, and should not be worse than the disease. A 2020 review reiterates that anogenital warts have significant morbidity and no established effective treatment.
Scissors excision of single warts was examined in a retrospective analysis of 85 patients from a larger placebo-controlled interferon study. At 4 and 16 weeks after excision, 19% and 21% of excised lesions recurred. After at least 6 months of follow-up, 18% of excision sites showed some pigmentation changes. The authors concluded that scissors excision has a high rate of success and acceptable long-term side-effects.
A single case report describes an 11-year-old child with recurrent anogenital warts treated with 10% sinecatechins ointment. After 10 weeks of application, the warts completely disappeared with no recurrence during 12 weeks of follow-up. The authors note sinecatechins appear reasonable for children who cannot tolerate painful destructive therapy. A 2010 study of 22 patients treated with intravenous panavir and topical panavir gel reported that 6 patients showed regression of warts by the end of the first month, while the other 16 required destruction with solcoderm. At 6 months, recurrence was observed in 1 case (4.5%). The authors reported good tolerance and high clinical effectiveness.
A 2023 retrospective analysis of patients diagnosed between 2010 and 2021 investigated the relationship between treatment options and recurrence, but the abstract does not report specific recurrence rates or comparative outcomes. What remains missing is a randomised controlled trial large enough to compare treatments head-to-head, with standardised follow-up and clear stratification by wart number, location, and immune status. Funding for such a trial, and a design that accounts for spontaneous clearance and patient-reported pain, is still absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatologic Therapy · 2004 · 54 citations
Therapy of external anogenital warts and molluscum contagiosum: a literature review
AbstractAnogenital warts and mollusca contagiosum are virally induced, benign skin tumors for which there is no single preferable therapy. Treatments include physical and chemical destruction, surgical removal, and biological response modifiers to enhance the natural immune response. The choice of therapy is an art, and depends upon patient preference, finances, number of lesions, and lesional morphology. However, the therapy of these lesions can sometimes be very painful and expensive, and therapy should not be worse than the disease.
Therapeutic Efficacy and Complications of Excisional Biopsy of Condyloma acuminatum
AbstractBACKGROUND AND OBJECTIVES: Among the various treatment modalities for condyloma acuminatum, excisional cold-blade surgery appears excellent but it has been little studied and little used, particularly for lesions not located in the perianal area. GOALS: To examine the efficacy and complications of scissors excision of single anogenital warts. STUDY DESIGN: Retrospective analysis of single warts completely excised with scissors for the purpose of biopsy before patient entry in a randomized, placebo-controlled study of the efficacy and safety of various parenteral interferons in combination with cryotherapy. RESULTS: Of 152 patients entered in the main study, 85 patients were available for analysis. At 4 and 16 weeks after excision, 16 of 85 (19%) and 14 of 68 (21%) of the excised lesions recurred. After at 6 least months of follow-up, 2 of 11 (18%) of the excision sites demonstrated some evidence of pigmentation changes. CONCLUSIONS: Scissors excision of single anogenital warts has a high rate of success and acceptable long-term side-effects.
The Pediatric Infectious Disease Journal · 2016 · 10 citations
Successful Treatment with 10% Sinecatechins Ointment for Recurrent Anogenital Warts in an Eleven-Year-Old Child
AbstractTreatment of anogenital warts was successful in an 11-year-old child with sinecatechins ointment 10%. After application for 10 weeks, the warts completely disappeared, without recurrence during a 12-week follow-up. Treatment was well tolerated, without notable side effects. Sinecatechins appear to be a reasonable treatment for anogenital warts in children who have difficulty tolerating painful destructive therapy.
Giornale Italiano di Dermatologia e Venereologia · 2020 · 7 citations
Anogenital warts treatment options: a practical approach
AbstractAnogenital warts (AGWs) are an important issue for public health centers dealing with Sexually Transmitted Infections. They are epidemiologically relevant, with significant morbidity and an established effective treatment is lacking. In this article, we examine the epidemiological, diagnostic, and therapeutic aspect of the problem in order to give an up to date picture of the situation and a practical clue for the management of AGWs.
Journal of Health Sciences and Medicine · 2023 · 2 citations · open access
Analysis of the relationship between clinical features, treatment options and recurrence of patients diagnosed with anogenital warts
AbstractAims: Our study aimed to describe the demographic and clinical characteristics of patients with anogenital warts and to investigate the relationship between treatment options and recurrence. Methods: The data of patients who were admitted to the dermatology, urology, and gynecology outpatient clinics between 2010 and 2021, and diagnosed with anogenital warts were retrospectively analyzed. Demographic characteristics of the patients, presence of other sexually transmitted diseases, anatomical distribution of warts, number of anatomical regions and warts, frequency of recurrence, type of treatment before the first recurrence, and follow-up periods were documented. Statistical analysis was performed and the results were evaluated at a 95% confidence interval and p
Health and Ecology Issues · 2010 · 0 citations · open access
EXPERIENCE OF THE APPLICATION OF PANAVIR IN THE TREATMENT OF PATIENTS WITH HUMAN PAPILLOMAVIRUS OF ANOGENITAL REGION
AbstractIn the article the results of the treatment of 22 patients with anogenital warts have been presented. The treatment began with an intravenous injection of 0,004 % solution of panavir per 5 ml. (first 3 injections at the interval of 48 hours, then 2 injections at the interval of 72 hours), exterior treatment included daily 3-4 applications of panavir gel. 6 patients displayed regress of anogenital warts by the end of the first month of the screening period, the other 16 underwent the destruction of anogenital warts with solcoderm in the end of the first month of screening period. 6 months later recurrence was observed only in 1 case (4,5 %). The conclusion was made about good tolerance and high clinical effectiveness of the given treatment method.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
